Upadacitinib for Treatment of Granulomatous Cheilitis

JAMA Dermatol. 2024 Sep 1;160(9):1001-1003. doi: 10.1001/jamadermatol.2024.2378.

Axel De Greef^{1

2}, Caroline Peeters¹, Olivier Dewit^{3

4}, Laurence de Montjoye^{1

2}, Marie Baeck^{1

2}

¹ Department of Dermatology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
² Institute of Experimental and Clinical Research (IREC), Pneumology, ENT and Dermatology Pole (LUNS), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
³ Department of Gastroenterology, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
⁴ Institute of Experimental and Clinical Research (IREC), Pole of Research in Hepato-Gastroenterology (GAEN), Université catholique de Louvain (UCLouvain), Brussels, Belgium.

No abstract available

Plain language summary

This case series examines the effectiveness of the Janus kinase inhibitor upadacitinib for the treatment of granulomatous cheilitis.